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model of the disease or an in vitro model that provides a
meaningful simulation of it. Therefore, investigation of such
new technology in human beings requires active communi-
cation between trial sponsors, government regulators who
are exercising oversight, and clinicians who are primarily
responsible for the outcomes that are used to evaluate safety
and efficacy.
This report summarizes experience with an aortic endo-
graft during an investigative clinical trial that yielded satisfac-
tory results at an early stage, followed by additional
follow-up observations that show a limited number of
device-specific failure types. An interactive process between
clinicians and industry trial staff of analysis of clinical obser-
vations, hypothesis generation, and in vitro testing lead to
design modification.
MATERIALS AND METHODS
This was a prospective, hypothesis-testing clinical trial
approved by the United States Food and Drug
Administration (FDA) through the investigative device
The treatment of aortic aneurysm by remote access
through catheter-based procedures is an idea with intuitive
appeal because of its minimally invasive features. However,
abdominal aortic aneurysm lacks a satisfactory in vivo animal
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Purpose: Analysis endpoints of patient survival and aortic rupture at a reporting interval of 12 months are regularly used to
compare endograft aortic aneurysm (EAG) repair to conventional open surgical (COS) repair. This study reports a multicen-
ter EAG repair versus COS repair parallel cohort trial at 12 months and additional observations of specific device failure types
and their impact on an aortic endograft design beyond that follow-up period.
Methods: From August 1997 to September 1998, 240 patients who were treated with bifurcation EAG repairs and 28 patients
who were treated with straight EAG repairs were compared with 98 patients who were treated with COS repair for elective
infrarenal aortic aneurysm repair. Allocation to treatment was based on aneurysm anatomy. All cohorts underwent infrarenal
procedures. Data from concurrent, nonrandomized patient accrual from 17 United States institutions were prospectively
gathered and independently adjudicated for safety and efficacy. An independent core laboratory evaluated all imaging data.
Results: There were 308 men and 58 women (mean age, 72 years; range, 42-94 years) treated for infrarenal aortic aneurysm
(mean diameter, 55 mm; range, 40-115 mm). Mean preoperative aneurysm diameters were clinically similar (EAG repair, 54
mm vs COS repair, 57 mm). The two cohorts were not significantly different in terms of gender (P = .30) or age (P = .32).
EAG repair technical success (aneurysm exclusion, graft patency, patient survival) at 30 days was 89.2%. Five patients required
immediate conversion to COS repair, four caused by access complications and one caused by operator-induced EAG repair mal-
position. The 30-day mortality rate was 1.5% for EAG repair and 3.1% for COS repair (P = .59). The 12-month survival rate
was 94.3% for EAG repair and 95.9% for COS repair. The intermediate-term cumulative survival rate at 24 months was 84.9%
for EAG repair and 80.3% for COS repair (P = .48). EAG repair device failure occurred from fabric erosion in six patients, with
two deaths from ruptured aneurysm at 18 and 28 months after endografting and four device failures resolved by secondary
procedures. Five endograft limb dislocations were all resolved by secondary endovascular procedures. Major or minor endograft
migration required secondary procedures in five patients, including conversion in two patients.
Conclusion: The clinical outcome at 12 months demonstrated effective aneurysm treatment and comparable safety between
EAG repair and COS repair by conventional endpoints. Ongoing follow-up beyond 12 months revealed device-related adverse
events that required endograft design changes. Diligent surveillance of outcomes beyond 12 months is necessary to adequately
evaluate EAG repair devices. (J Vasc Surg 2001;33:S55-63.)
exemption process. The primary objective of this study
was to evaluate the effectiveness of the Vanguard aortic
aneurysm endograft (EAG) repair in excluding infrarenal
aortoiliac aneurysms to protect patients from death from
aneurysm rupture. An assessment of safety was made by
comparison with conventional open surgical (COS) repair.
Seventeen centers, each with participation by staff
physicians from vascular surgery and interventional radi-
ology specialties (Appendix 1), enrolled patients into
both COS and EAG repair cohorts. Beginning on August
5, 1997, to September 14, 1998, 240 patients who
received bifurcation endografts, 28 patients who under-
went straight EAG repair, and 98 patients who under-
went COS repair were entered into study groups.
Enrollment was concurrent but not randomized.
Comorbidity and traditional operative risk factors were
similar for each group. Assignment to treatment type was
based primarily on aortoiliac anatomy. Each study site was
asked to concurrently recruit six conventional surgery
repair patients into a study cohort of adequate size for
statistical comparison as determined before the trial by
the sponsor and FDA biostatisticians. All patients
JOURNAL OF VASCULAR SURGERY
S56 Beebe et al February 2001
Fig 1. Cumulative survival rates compare EAG repair and COS repair. The EAG repair survival rate is greater than COS repair survival
rate at 1 month and 24 months, a trend that did not reach statistical significance.
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received infrarenal procedures for prosthetic replacement
of the aneurysmal vascular segments.
Patients were eligible for the trial if they were of aver-
age surgical risk and had an infrarenal aortic aneurysm that
was 50 mm or larger in maximum transverse diameter.
Patients with aneurysms smaller than that size could also be
entered into the trial if they had documented imaging evi-
dence of expansion of 5 mm or more within the preceding
12 months, symptomatic aneurysm (typical abdominal pain
without other explanation), hypertension (systolic blood
pressure or diastolic blood pressure, >140/90 mm Hg), or
documented chronic obstructive pulmonary disease (exer-
tional FEV1, <50% of predicted; resting FEV1, <25% of
predicted). Patients with aortoiliac aneurysms were also
included if both internal iliac arteries did not need to be
occluded to exclude the aneurysms. Patient exclusions
from the trial included a ruptured aneurysm, a serum cre-
atinine level of more than 1.7 mg/dL, a dominant inferior
mesenteric artery, the presence of a horseshoe kidney,
chronic anticoagulant therapy, a probable life expectancy of
less than 1 year, the presence of a vascular prosthesis, a
stent or any investigational implant, pregnancy, a systemic
groin infection, previously documented allergy to contrast
media, known antibody to heparin, obesity compromising
visualization, an unwillingness to sign informed consent or
an inability to comply with the follow-up schedule, an
aneurysm with Marfan’s syndrome as the cause, a mycotic
aneurysm, and current participation in any other experi-
mental protocol or drug trial. All patients received detailed
information about the investigational nature of the trial
and gave informed consent to participate. Each study site’s
participation and results were independently evaluated by
its institutional review board.
Anatomic limits for critical attachment zones included
a proximal infrarenal aortic diameter exceeding 25 mm or
less than 20 mm, a length less than 15 mm below the most
distal renal artery, an angulation greater than 60 degrees
between neck and aneurysm, a severe angulation of exter-
nal or common iliac arteries, less than 15 mm length of
nonaneurysmal common iliac artery available above the
iliac bifurcation, or if the distal common iliac or external
iliac artery attachment site was greater than 13 mm in
diameter. Follow-up protocol required serial imaging stud-
ies at 1, 3, 6, 12, 18, and 24 months to assess aortoiliac
morphologic change, device position, presence of endoleak
and prosthesis patency by investigative sites, and a core
imaging laboratory in addition to clinical evaluation. 
Efficacy of the device to successfully exclude the
aneurysm was evaluated with a combined endpoint of
death, conversion to open surgery, presence of unresolved
Fig 2. Freedom from all-cause endoleak for all EAG repairs. This type of analysis commingles endoleaks of all types without an indica-
tion of severity. The comparison of these data with that shown in Fig 3 will allow an understanding of those endoleaks that sealed spon-
taneously or by secondary endovascular intervention.
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endoleak, or device thrombosis at 12-month follow-up.
Clinical utility endpoints included estimated blood loss
during the implantation procedure, the number of hours
the patient stayed in the intensive care unit, and the length
of hospital stay (defined as days between implantation and
discharge). Data analysis endpoints for safety were death,
primary patency including occlusion of the device or occlu-
sion of the native vessel immediately proximal or distal to
the device, endoleak, and device structural failure. Patient
demographic parameters were compared with the use of
the binary proportion method; continuous variable com-
parisons were performed using a two-sample, unequal vari-
ance t-test method. Life survival was calculated with the
product-limit method (Kaplan-Meier), with groups com-
pared with the use of the log-rank and generalized
Wilcoxon tests.
Device description. The Vanguard (Boston Scientific
Corporation, Natick, Mass) aortic bifurcated stent graft is
a modular device comprised of polyethylene fabric that is
supported throughout its full length by self-expanding,
thermal-activated nitinol stents that are arranged in inde-
pendent rows of “zig-zag” configuration within the fabric
tube. Open stents extend above the fabric at the upper-
most 11 mm of the proximal endograft; there are six exter-
nal wire barbs that are intended to enhance friction at that
location. Nominally, the endograft consists of two compo-
nents that are assembled in situ within the aortoiliac
anatomy, the aortic trunk that includes the ipsilateral iliac
limb, and a contralateral iliac limb docking or “stump”
orifice contained within a 21F delivery sheath. The other
component is the contralateral iliac limb, which is inserted
into the aortic trunk through contralateral arterial access
with a 12F sheath. The rows of stents are fastened to each
other by a series of 322 polypropylene ties (size 60) that
do not traverse the endograft fabric.
The fabric is attached to stents at the proximal and dis-
tal stent ends of the device by polyethylene sutures (size
60). Although the device is self-expanding when exposed
to physiologic temperature, a latex low pressure (≤1 atm)
or another balloon is normally used during insertion
throughout the entire endograft to obviate fabric wrinkles.
A range of sizes for the aortic/ipsilateral limb and con-
tralateral limb components could be selected to accom-
modate anatomy within the protocol limits. When
additional length was required to cross the iliac artery
bifurcation unilaterally, extensions similar to the initial
contralateral limb were used. Nominal overlap between
iliac endograft components were 12 mm at the aortic
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Fig 3. Freedom from persistent endoleak rate.
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stump and usually a greater amount if iliac artery exten-
sions were used.
RESULTS
There were 308 men and 58 women (mean age, 72
years; range, 42-94 years) entered into the trial. Of these,
240 patients received bifurcation endografts; 28 patients
received straight configuration endografts (EAG repair), and
98 patients were treated with COS repair. The mean maxi-
mum diameter of treated aneurysms was clinically similar
between EAG repair (54 mm) and COS repair (57 mm),
with a range of 40 to 115 mm for all groups. 
The two cohorts, EAG repair and COS repair, were not
significantly different in age (P = .32) or gender (P = .30).
Smoking history (current or former) was significantly different
between groups, 230 smokers (85.8%) in the EAG repair
group and 95 smokers (97.9%) in the COS repair group (P =
.001). Occurrence of other conventional risk factors was sim-
ilar between the two treatment cohorts, EAG repair and COS
repair, respectively: hypertension, 153 patients (57.1%) versus
63 patients (64.9%); diabetes, 32 patients (11.9%) versus six
patients (6.2%); history of myocardial infarction, 88 patients
(32.8%) versus 38 patients (39.2%); and chronic obstructive
pulmonary disease, 82 patients (30.6%) versus 33 patients
(34.0%), with probability values greater than .05 for all factors.
Short-term results analysis showed the mortality rate at
30 days was 3.1% (3/98 patients) in COS repair and 1.5%
(4/268 patients) in EAG repair, a trend that did not reach
statistical significance (P = .59). The cause of death in EAG
repair was cardiac in three patients and respiratory failure in
one patient. One patient in the open surgical repair group
died of mesenteric infarction; one patient died of hepatic fail-
ure, and one patient died of cardiac complications. Five
patients who had undergone EAG repair were converted to
COS repair at the time of attempted EAG repair. The cause
of conversion was related to iliac artery transit problems in
the application of the endograft delivery system in four
patients with marked arterial calcification and tortuosity and
to malposition of the endograft in one patient. There were
no deaths associated with EAG repair conversion to COS
repair.
Primary freedom from all-cause endoleak at 30 days
among patients who underwent EAG repair was 94.3%,
but at 3 months the freedom from persistent endoleak rate
was 97.3%. Primary patency analysis at 30 days revealed a
100% rate in COS repair and a 98.1% rate in EAG repair.
Analysis of hospital resource use revealed significant dif-
ferences between groups. Mean hospital length of stay was
3.6 days ± 4.6 (SD) for EAG repair and 9.0 ± 7.4 days for
COS repair (P < .001), although intensive care unit stay
Fig 4. Cumulative freedom from secondary device intervention for endoleak and/or limb dislocation. A bimodal pattern seems evident
with early procedure-related adjustments within the first month and an increase in the later interval of 6 to 24 months.
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was similarly less for EAG repair 20.6 ± 65.2 hours versus
78.1 ± 135.5 hours for COS repair (P < .001). Mean
blood transfusion requirements were 457.2 ± 827.4 mL
for EAG repair and 1367.5 ± 1306.5 mL for COS repair
(P < .001).
Intermediate-term cumulative survival rates at 12 and
24 months, respectively, were 93.2% and 84.9% for EAG
repair and 95.7% and 80.3% for COS repair, but these dif-
ferences did not reach statistical significance (Fig 1). The
cumulative primary freedom from all-cause endoleak rate
declined from 94.3% at 1 month to 81.2% at 18 months
and 65.9% at 24 months, with a total of 41 endoleaks of
all types observed (Fig 2). This type of overall analysis
does not reflect sealed endoleaks. The freedom from per-
sistent endoleak rate is shown in Fig 3. Of 15 early
endoleaks observed within 1 month, 10 sealed sponta-
neously or were sealed by secondary endovascular inter-
vention in five patients. The first occurrence of endoleak
had a bimodal pattern. Fifteen endoleaks occurred in the
first month, but only five endoleaks occurred after that
until 6 months. There was a significant increase from 6 to
18 months (with 16 endoleaks occurring) and from 18 to
24 months (with five more endoleaks occurring); this was
an event termed secondary endoleak. There were 28 sec-
ondary interventions of various types for endoleak of all
causes or limb dislocation among all patients who under-
went EAG repair and whose cases were followed for 24
months (Fig 4).
Limb occlusions occurred throughout a similar obser-
vation interval in 17 patients who underwent EAG repair,
which resulted in a cumulative freedom from secondary
intervention rate for thrombosis of 95.4% ± 1.3% at 12
months and 85.8% ± 4.6% at 24 months. No patient expe-
rienced limb loss in the EAG repair group; however, two
patients in the COS repair group required above-knee
amputation as the result of ischemic complications. The
freedom from secondary intervention rate for all causes is
shown in Fig 5. No patient in the COS repair cohort
required secondary intervention throughout 24 months of
observation. 
Late device failure. Three types of late device failure
were observed, most occurring beyond 12 months and
causing secondary endoleak. There were six cases of fab-
ric erosion that were caused by abrasion of the polyester
woven fabric from contact with the underlying stent,
which resulted in a type III endoleak. All but one
endoleak occurred at 18 months or longer after endograft
insertion. Aneurysm size among the six cases ranged from
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Fig 5. Freedom from secondary device intervention for any reason. This analysis includes indications for secondary intervention, such
as thrombosis or migration beyond the specific device failure issues of fabric erosion and limb dislocation shown in Fig 4.
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5.1 cm to 7.4 cm, and all patients received bifurcated
endografts.
Five cases of dislocation of the contralateral endograft
limb from the aortic trunk that led to a type III endoleak
were all treated successfully by secondary endovascular
procedures. Device migration of more than 1 cm occurred
in 15 cases, but only five of these cases were considered
device failure because they required secondary endovascu-
lar treatment or conversion. The remainder were still
being followed without reintervention at the time of this
report. Three migrations were treated by secondary endo-
graft procedures with clinically satisfactory outcome, and
two migrations were converted to COS repair. Of the total
of 16 device failures, there were 14 satisfactory early
results and two deaths (Table I).
Case report. The first case of fabric erosion in the US
trial occurred on October 1, 1998, 6 months after implan-
tation, in a 76-year-old woman with a 5.1-cm diameter
abdominal aortic aneurysm and severe medical comorbid-
ity. The Vanguard implantation procedure was uneventful,
taking a total of 50 minutes. A computed tomography
(CT) scan at 1 day after operation was judged unremark-
able at the time but, on later review, was thought to show
a type II endoleak arising from the lumbar arteries. Her
course was uneventful for 6 months. At 6 months, acute
abdominal pain and repeat CT scan showed a large sec-
ondary endoleak and an enlarged abdominal aortic
aneurysm led to urgent surgery for a presumed ruptured
aneurysm; however, rupture was not an operative finding.
Successful conversion to COS repair was accomplished,
and the explanted endoprosthesis was submitted to
detailed examination. Multiple areas of fabric erosion that
appeared to be related to perforation by the underlying
stent were demonstrated (Fig 6). Evaluation was compli-
cated by the presence of unusual major calcification pro-
jections into the aortic lumen, shown on CT scan and by
operative findings, some of which aligned exactly by fabric
holes. The patient made a full recovery and remains well
at 19 months after the second operation.
This initial fabric erosion case, occurring in the US
Vanguard trial at 6 months after implantation, led to the
postulation of a theoretic mechanism that included
enabling factors acting together: (1) angulation of the
prosthesis within the aneurysm sac that leads to promi-
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Table I. Device failures
Time to 
Case event (mo) Indication/symptoms Procedure/treatment Follow-up
Fabric erosion
1 6 Type III endoleak; acute abdominal Conversion to open repair Well, 19 mo after operation
pain; not ruptured
2 18 Type III endoleak; acute abdominal Treatment refused Died
pain; ruptured
3 24 Type III endoleak Conversion to open repair Well, 30 mo after operation
4 24 Type III endoleak; acute abdominal Secondary endograft Well, 29 mo
pain; ruptured (cuff and limbs)
5 26 Type III endoleak Secondary endograft (cuff) Well, 27 mo
6 28 Type III endoleak; acute abdominal Conversion to open repair Died 1 week after operation
pain; ruptured
Endograft limb dislocation
1 1 Type III endoleak Secondary endovascular  Sealed
implantation of two extensions
2 7 Type III endoleak Secondary endovascular  Sealed
implantation of extension
3 13 Type III endoleak Secondary endovascular  Sealed
implantation of extension
4 18 Type III endoleak Secondary endovascular Sealed
implantation
5 20 Type III endoleak Secondary endovascular Sealed
implantation of extension
Endograft migration
1 3 10-mm Migration; distal type I Secondary endograft procedure Well, 16 mo
secondary endoleak at 12 and 16 mo at 14 mo; additional endograft
procedure at 16 mo
2 12 17-mm Migration Conversion at 13 mo because Well, 15 mo
of occlusion
3 12 38-mm Migration Conversion at 18 mo because Well, 18 mo
of migration
4 12 30-mm Migration; distal type I Bifurcated EAG deployed Endoleak sealed; 
secondary endoleak inside straight at 16 mo well, 25 mo
5 12 13-mm Migration; distal type I Secondary endovascular Endoleak sealed; 
secondary endoleak at 18 mo procedure; bilateral iliac well, 18 mo
extensions at 18 mo
nence of one or more stent angle apices and (2) motion of
the overlying endograft fabric made possible because of a
lack of restraining thrombus outside the stent graft in a sac
with preexisting type II endoleak. These conditions were
simulated by in vitro testing and produced confirming evi-
dence of fabric erosion (Fig 7). However, observation of
later cases that occurred 18 to 24 months after implanta-
tion have not been associated with preexisting endoleak.
This version of the Vanguard aortic stent-graft was with-
drawn from clinical use for technical reasons after this trial.
DISCUSSION
In the early years of endografting for aneurysm treat-
ment, much emphasis was placed on the avoidance of
operative morbidity and thereby the conservation of hos-
pital resources including early discharge, lesser intensity of
care, and freedom from blood transfusion. Short-term
benefits in these measures were shown in this study for the
EAG repair cohort compared with the COS repair cohort.
There was a trend towards a lower operative mortality rate
in patients who underwent EAG repair (one half that of
COS repair), the statistical significance of which was lim-
ited by sample size. Similar findings of this type of early
benefit have been observed in virtually every report of an
endograft series.1-3
As worldwide endograft experience accumulated, the
focus of attention turned toward appropriate patient selec-
tion while emphasizing vascular morphologic features and
the important issue of follow-up. At the 12-month assess-
ment, the EAG repair cohort in this study had realized sat-
isfactory benefit in terms of the primary treatment goal of
aneurysm exclusion. However, the requirement for sec-
ondary procedures was higher than that of the COS repair
cohort, a trade-off associated with evolving technology
and with an exchange for the distinctly lower morbidity of
the initial procedure to treat the aneurysm. In this investi-
gational trial, the 12-month results of treatment could be
judged comparable with those reported in proceedings of
US government regulatory oversight by developers of the
two endograft devices that have received conditional
approval for commercial sale and general use.4,5
The need for ongoing “maintenance” procedures after
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Fig 6. The posterior aspect of the aorta (A) and the endograft within it (B) by computerized processing of CT scan taken immediately
before explantation (Medical Media Systems, Hanover, NH). H, Locations of the observed fabric erosion holes on the posterior aspect
of the prosthesis. C, A scanning electron micrograph (×25) of a typical appearance of one of the fabric holes.
Fig 7. Two representative samples from in vitro simulation testing of the Vanguard stent graft under various conditions of angulation
and compression. A, Flattening of polyethylene fibers can be seen from repeated cycles of compression against a flat stent wire without
erosion that produces a hole. B, Fabric erosion that resulted in a hole after similar repeated compression cycles against the apex of an
angled “zig-zag” stent.
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endografting has been noted by others. Becquemin et al6
noted that endovascular aneurysm treatment in 75
patients who were observed for a mean of 18 months
resulted in the necessity for 21 subsequent endovascular or
vascular procedures in 17 patients (23%) to treat graft limb
occlusion or stenosis (n = 9 patients) or to seal an
endoleak (n = 8 patients). The 2-year cumulative survival
rate free of reintervention was 67% ± 7% in the French
Vanguard trial. Use of the Ancure endograft device
(Guidant Corporation, Menlo Park, Calif) has been
reported to require secondary procedures for endoleak or
limb occlusion.7,8 Amesur et al8 elected to place additional
endovascular devices as an adjunct to prevent endograft
limb occlusion in 46% of their bifurcation endoprostheses.
Zarins et al,2 in an endograft trial of 190 patients who
were treated with the Aneurx stent graft (Medtronic,
Santa Rosa, Calif), described an 8.4% rate of secondary
procedures: 11 procedures for endoleak, three procedures
for migration, and five procedures for graft limb throm-
bosis within 12 months.
Aortic aneurysm rupture after apparently successful
endovascular exclusion involving a variety of devices in
current use has been reported by an increasing number of
authors.9-16 The first known Vanguard endograft failure
caused by fabric erosion was detected in September 1997
by angiography but was not proved until 6.5 months later
at the time of conversion to open repair.17 Treatment of
the type III endoleak by a secondary endovascular graft
procedure was initially successful, but 8 months later a
type III endoleak recurred because of graft limb disloca-
tion. The separation of components of a modular endo-
graft that is assembled in situ during the implantation
procedure has caused rupture in the use of other devices,
also. Zarins et al18 reported seven cases of aneurysm rup-
ture at a mean interval of 15 months (range, 3 weeks–24
months) after endografting among 1046 patients in vari-
ous phases of the U S Aneurx Multicenter Clinical Trial.
Five deaths occurred after attempted salvage by conver-
sion to COS repair. A variety of fixation failures and/or
component separation occurred, but fabric erosion was
not observed.
The early experience with device failure described by
Moore and Rutherford19 is an example not only of such
an occurrence but also of successful treatment by the
reengineering of components of the Ancure device, which
later received regulatory approval for general use. The
process of clinical observation that led to engineering
analysis of adverse events followed by device modification
and subsequent reintroduction into clinical investigative
use is also demonstrated by the experience reported here.
A redesign of the Vanguard aortic stent graft has resulted
in several modifications that are now incorporated into the
currently manufactured endograft, which is known as
Vanguard III. This new product was introduced into clin-
ical trials in Europe in June 2000 and is in the process of
being submitted to the FDA in the United States for
investigational device exemption status. Although the inci-
dence rate of device failure by fabric erosion was relatively
small, 2.2% (6/268 patients), the importance was high
enough to warrant design review and change. This is espe-
cially compelling in the context of the treatment of
patients with average surgical risk for conventional surgi-
cal repair because, as Zarins20 has recently observed,
“Endovascular stent grafts are new devices of various
designs, and all potential failure modes are not yet
known.”
Although still a relatively short interval of time and a
small number of observed patients, the survival of patients
who were treated with EAG repair in this study is compa-
rable to those patients who were treated with COS repair
and to recent reports of conventional surgical repair.
Johnston,21 reporting for the Canadian Society for
Vascular Surgery Aneurysm Study Group, found a 24-
month survival rate of 87.1% after elective open repair that
declined to 81.0% at 3 years on the basis of all-cause mor-
tality rates.
May et al,22 in summarizing a large and extended
endograft experience, observed that aortic aneurysms have
the paradoxical effect of distorting the endograft that has
induced them to shrink after successful exclusion from the
circulation. The physical stress of such change may pro-
voke secondary changes in the alignment of elements
within an endograft or cause traction to affect the rela-
tionship between components. Microscale movement
between device elements of dissimilar materials may cause
erosion and subsequent loss of integrity. This phenome-
non was observed clinically in the six cases reported here.
The ability to simulate this phenomenon in vitro was
demonstrated as well, thus providing the basis for the test-
ing of device modifications to validate improvement.
Aortic aneurysm is a disease that lacks an animal
model or in vitro simulation with sufficient verisimilitude
to permit a definitive evaluation of prosthetic devices
before human investigational use. Therefore, the applica-
tion of implantable devices to protect patients from
aneurysm rupture requires vigilant follow-up observation
of both clinical outcome and device performance. Clinical
success at 12 months in protection from aneurysm rupture
was demonstrated in this study. Based on further results of
this aortic stent graft trial, two elements of that follow-up
process deserve special emphasis. First, ongoing detailed
observations beyond the standard 12-month interval are
needed, because the real test of endovascular aneurysm
treatment is to be found in the assessment of long-term
protection from aneurysm rupture. Second, interactive
communication during long-term follow-up between
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device developers and clinicians who are investigating the
performance of devices in trials is a prerequisite to achieve-
ment of maximum patient benefit.
The authors thank Jacki Stedman, MPH, Medical Editor, for
assistance with manuscript preparation.
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